The new cells prevented the onset of diabetes in an animal model of the disease bringing personalized cell therapy for diabetes closer.
Scientists at the Gladstone Institutes and the University of California, San Francisco (UCSF) have successfully converted human skin cells into fully-functional pancreatic cells. The new cells produced insulin in response to changes in glucose levels, and, when transplanted into mice, the cells protected the animals from developing diabetes in a mouse model of the disease.
The new study, published in Nature Communications, also presents significant advancements in cellular reprogramming technology, which will allow scientists to efficiently scale up pancreatic cell production and manufacture trillions of the target cells in a step-wise, controlled manner. This accomplishment opens the door for disease modeling and drug screening and brings personalized cell therapy a step closer for patients with diabetes.
“Our results demonstrate for the first time that human adult skin cells can be used to efficiently and rapidly generate functional pancreatic cells that behave similar to human beta cells,” says Matthias Hebrok, PhD, director of the Diabetes Center at UCSF and a co-senior author on the study. “This finding opens up the opportunity for the analysis of patient-specific pancreatic beta cell properties and the optimization of cell therapy approaches.”
In the study, the scientists first used pharmaceutical and genetic molecules to reprogram skin cells into endoderm progenitor cells—early developmental cells that have already been designated to mature into one of a number of different types of organs. With this method, the cells don’t have to be taken all the way back to a pluripotent stem cell state, meaning the scientists can turn them into pancreatic cells faster. The researchers have used a similar procedure previously to create heart, brain, and liver cells.
After another four molecules were added, the endoderm cells divided rapidly, allowing more than a trillion-fold expansion. Critically, the cells did not display any evidence of tumor formation, and they maintained their identity as early organ-specific cells.
The scientists then progressed these endoderm cells two more steps, first into pancreatic precursor cells, and then into fully-functional pancreatic beta cells. Most importantly, these cells protected mice from developing diabetes in a model of disease, having the critical ability to produce insulin in response to changes in glucose levels.
“This study represents the first successful creation of human insulin-producing pancreatic beta cells using a direct cellular reprogramming method,” says first author Saiyong Zhu, PhD, a postdoctoral researcher at the Gladstone Institute of Cardiovascular Disease. “The final step was the most unique—and the most difficult—as molecules had not previously been identified that could take reprogrammed cells the final step to functional pancreatic cells in a dish.”
Sheng Ding, PhD, a senior investigator in the Roddenberry Stem Cell Center at Gladstone and co-senior author on the study, adds, “This new cellular reprogramming and expansion paradigm is more sustainable and scalable than previous methods. Using this approach, cell production can be massively increased while maintaining quality control at multiple steps. This development ensures much greater regulation in the manufacturing process of new cells. Now we can generate virtually unlimited numbers of patient-matched insulin-producing pancreatic cells.”
The Latest on: Personalized cell therapy
via Google News
The Latest on: Personalized cell therapy
- ABEC CSR® Single-Use Fermenters to Support Catalent Cell & Gene Therapy Manufacturing Expansionon April 6, 2021 at 10:33 am
ABEC CSR single-use fermenters supplied to Catalent Cell & Gene Therapy on a fast-track schedule to support flexible manufacturing of plasmid DNA.
- GenomeFrontier, Ziopharm Non-Viral Vectors Could Transform CAR-T Cell Therapyon April 5, 2021 at 9:24 am
the Sleeping Beauty technology enables the rapid personalized manufacturing of genetically modified CARs and T-cell receptors (TCRs) right where the patient is receiving treatment. Ziopharm Chief ...
- Combination of tumor cell vaccine and checkpoint therapy creates effective immune responseon April 4, 2021 at 5:06 am
A personalized tumor cell vaccine strategy targeting Myc oncogenes combined with checkpoint therapy creates an effective immune response that bypasses antigen selection and immune privilege, according ...
- Personalized melanoma vaccines show lasting effectson April 2, 2021 at 7:08 am
Arecent study showed that personalized cancer vaccines designed to fight melanoma, the deadliest form of skin cancer, maintain their effects on the immune system years after inoculation—another step ...
- Radiation may contribute to personalized cancer vaccineon March 30, 2021 at 5:00 pm
The immune system is prompted to attack a foreign invader or an unhealthy cell ... therapy helps cancer cells become more visible to the immune system and works in concert with a personalized ...
- Cell and Gene Therapy Drug Delivery Devices Market, 2030 - Market Opportunities in the Strong Pipeline of Cell and Gene Therapieson March 30, 2021 at 2:15 pm
The "Global Cell and Gene Therapy Drug Delivery Devices Market: Focus on Product Type, Commercialized Drug Delivery Devices, Country Data (16 Countries), and Competitive Landscape - Analysis and ...
- bluebird (BLUE), Bristol Myers CAR T Cell Therapy Gets FDA Nodon March 30, 2021 at 10:19 am
Shares of bluebird bio, Inc. BLUE gained 3.2% after the company and its partner Bristol Myers Squibb BMY announced that the FDA has approved their chimeric antigen receptor (CAR) T cell immunotherapy ...
- Personalized Stem Cells Announces Stem Cell Knee Arthritis FDA-Approved Phase 1/2a Clinical Trial Resultson March 30, 2021 at 7:08 am
We are pleased at the strong safety profile and efficacy results in this FDA-approved clinical study of stem cell therapy for knee osteoarthritis.” — Dr. Bob Harman, PSC CEO POWAY, CALIFORNIA, US, ...
- Global Personalized Cell Therapy Market 2020 Leading Segments, Primary and Secondary Drivers, Key Players and Geographical Analysis by 2025on March 29, 2021 at 11:37 am
The MarketWatch News Department was not involved in the creation of this content. Mar 29, 2021 (CDN Newswire via Comtex) -- Global Personalized Cell Therapy Market Growth (Status and Outlook) ...
- FDA Approves First Anti-BCMA CAR T-Cell Therapy for Relapsed, Refractory Multiple Myelomaon March 29, 2021 at 7:39 am
In a clinical trial of idecabtagene vicleucel in multiple myeloma, the overall response rate for the efficacy evaluable population was 72%, and 28% of participants achieved a stringent complete ...
via Bing News